# Fitlife Brands, Inc.: overview FTLF · Nasdaq · CIK 1374328 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/ftlf.md) · [Financials](/companies/ftlf/financials.md) · [Filings](/companies/ftlf/filings.md) · [Insiders](/companies/ftlf/insiders.md) Latest reported revenue: [$26.5m](/filings/0001437749-26-027478.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-027478). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [16.0](/filings/0001437749-25-034607.md) | [15.0 d](/filings/0001437749-26-010680.md) | [15.9](/filings/0001437749-26-016875.md) | [16.1](/filings/0001437749-26-027478.md) | [23.5](/filings/0001437749-25-034607.md) | [(39.6) d](/filings/0001437749-26-016875.md) | [25.3](/filings/0001437749-26-016875.md) | [26.5](/filings/0001437749-26-027478.md) | | Gross margin | % | [43.8%](/filings/0001437749-25-034607.md) | [41.4% d](/filings/0001437749-26-010680.md) | [43.1%](/filings/0001437749-25-016990.md) | [42.8%](/filings/0001437749-26-027478.md) | [37.2%](/filings/0001437749-25-034607.md) | [39.5% d](/filings/0001437749-26-016875.md) | [37.6%](/filings/0001437749-26-016875.md) | [37.0%](/filings/0001437749-26-027478.md) | | Operating margin | % | [19.9%](/filings/0001437749-25-034607.md) | [19.2% d](/filings/0001437749-26-010680.md) | [18.6%](/filings/0001437749-25-016990.md) | [15.6%](/filings/0001437749-26-027478.md) | [9.9%](/filings/0001437749-25-034607.md) | [12.2% d](/filings/0001437749-26-016875.md) | [12.1%](/filings/0001437749-26-016875.md) | [12.6%](/filings/0001437749-26-027478.md) | | Net margin | % | [13.3%](/filings/0001437749-25-034607.md) | [13.8% d](/filings/0001437749-26-010680.md) | [12.7%](/filings/0001437749-26-016875.md) | [10.8%](/filings/0001437749-26-027478.md) | [3.9%](/filings/0001437749-25-034607.md) | [6.7% d](/filings/0001437749-26-016875.md) | [6.8%](/filings/0001437749-26-016875.md) | [7.3%](/filings/0001437749-26-027478.md) | | Diluted EPS | $ per share | [0.21](/filings/0001437749-25-034607.md) | not reported | [0.20](/filings/0001437749-25-016990.md) | [0.18](/filings/0001437749-26-027478.md) | [0.09](/filings/0001437749-25-034607.md) | not reported | [0.17](/filings/0001437749-26-016875.md) | [0.20](/filings/0001437749-26-027478.md) | | Free cash flow | $m | [2.0 d](/filings/0001437749-25-034607.md) | [1.0 d](/filings/0001437749-26-010680.md) | [2.3](/filings/0001437749-26-016875.md) | [1.2 d](/filings/0001437749-26-027478.md) | [3.7 d](/filings/0001437749-25-034607.md) | [0.2 d](/filings/0001437749-26-010680.md) | [2.5](/filings/0001437749-26-016875.md) | [3.6 d](/filings/0001437749-26-027478.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [27.9](/filings/0001437749-23-007858.md) | [28.8](/filings/0001437749-24-010119.md) | [52.7](/filings/0001437749-25-009469.md) | [64.5](/filings/0001437749-26-010680.md) | [15.9](/filings/0001437749-26-016875.md) | | Gross margin | % | [44.8%](/filings/0001437749-23-007858.md) | [41.8%](/filings/0001437749-24-010119.md) | [40.7%](/filings/0001437749-25-009469.md) | [43.6%](/filings/0001437749-26-010680.md) | [43.1%](/filings/0001437749-26-016875.md) | | Operating margin | % | [22.3%](/filings/0001437749-23-007858.md) | [19.8%](/filings/0001437749-24-010119.md) | [14.3%](/filings/0001437749-25-009469.md) | [20.3%](/filings/0001437749-26-010680.md) | [18.6%](/filings/0001437749-26-016875.md) | | Net margin | % | [19.4%](/filings/0001437749-23-007858.md) | [15.4%](/filings/0001437749-24-010119.md) | [10.0%](/filings/0001437749-25-009469.md) | [13.9%](/filings/0001437749-26-010680.md) | [12.7%](/filings/0001437749-26-016875.md) | | Diluted EPS | $ per share | [1.13](/filings/0001437749-23-007858.md) | [0.89](/filings/0001437749-24-010119.md) | [0.54](/filings/0001437749-25-009469.md) | [0.91](/filings/0001437749-26-010680.md) | [0.20](/filings/0001437749-26-016875.md) | | Free cash flow | $m | not reported | [4.1](/filings/0001437749-24-010119.md) | [4.1](/filings/0001437749-25-009469.md) | [9.6](/filings/0001437749-26-010680.md) | [7.4](/filings/0001437749-26-010680.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ftlf/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.7m | 154,255 | | Reduced −352 | | [HORIZON KINETICS ASSET MANAGEMENT LLC](/funds/1056823.md) | 2026-06-30 | $1.6m | 145,000 | | Reduced −9,456 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $540.3k | 49,045 | | Reduced −38,632 | | [Mink Brook Asset Management LLC](/funds/2052205.md) | 2026-06-30 | $513.5k | 46,637 | | Added +17,993 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $388.4k | 35,275 | | Reduced −122,129 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $288.7k | 26,219 | | Added +1,277 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $258.2k | 23,453 | | New +23,453 | | [Mariner, LLC](/funds/1373442.md) | 2026-06-30 | $242.3k | 22,006 | | New +22,006 | | [BARD ASSOCIATES INC](/funds/1105907.md) | 2026-06-30 | $233.2k | 21,177 | | Added +1,211 | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $198.2k | 18,005 | | New +18,005 | ## Recent filings [All 509 filings](/companies/ftlf/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-09 | 16:06 ET | [8-K](/filings/0001437749-26-029979.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-029979 | | 2026-08-13 | 08:30 ET | [8-K](/filings/0001437749-26-027493.md) | 2.02 Results of operations; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-027493 | | 2026-08-13 | 07:30 ET | [10-Q](/filings/0001437749-26-027478.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027478 | | 2026-06-26 | 12:15 ET | [DEF 14A](/filings/0001437749-26-021797.md) | Proxy statement, period 2026-08-11 | 0001437749-26-021797 | | 2026-05-22 | 16:09 ET | [8-K](/filings/0001437749-26-018249.md) | 5.02 Departure or appointment of officers or directors | 0001437749-26-018249 | | 2026-05-14 | 14:00 ET | [8-K](/filings/0001437749-26-016983.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-016983 | | 2026-05-14 | 07:30 ET | [10-Q](/filings/0001437749-26-016875.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016875 | | 2026-04-21 | 17:00 ET | [10-K/A](/filings/0001437749-26-012937.md) | Annual report, amended, period 2025-12-31 | 0001437749-26-012937 | | 2026-04-07 | 16:23 ET | [8-K](/filings/0001437749-26-011607.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-011607 | | 2026-04-01 | 08:00 ET | [8-K](/filings/0001437749-26-010811.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-010811 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010680.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/8d6ab644-d7c6-4acc-b575-0925858b0597) ## About the filer - CIK: 1374328 - Tickers: FTLF - Exchange: Nasdaq - SIC code: 2833 Medicinal Chemicals & Botanical Products - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.